Date: 2026-08-03. Tests seed hypotheses H7.1–H7.2.
Hypothesis verdicts
H7.1 (opioid settlement funds spent with weaker evidence requirements than the litigation's theory of harm demanded) — Supported. Convergent evidence from three independent institutions co-producing the same tracking project (KFF Health News, Johns Hopkins Bloomberg School, Shatterproof): enforcement of the contractual 85%-abatement requirement is left to the paying companies themselves, only 12 states commit to detailed itemized public reporting, and a full third of funds remained un-earmarked as of the latest complete national data. A November 2025 follow-up documented **>61Mspentonlawenforcementin2024alone * *, includingriflesuppressors, Tasers, andvehicle/gunpurchases—spendingwithnoestablishedevidencebaseforreducingoverdosedeathsandnoclearconnectiontothelitigation′sowndeceptive − marketing/oversupplytheoryofharm.Realevidence − alignedspendingexiststoo(>615M treatment, >$490M harm reduction nationally in 2024), so this isn't uniform diversion — but oversight to confirm evidence-basis is largely absent.
H7.2 (legal cannabis under-displaces illicit supply where tax+regulatory cost exceeds the illicit price premium) — Supported, for the two best-documented mature markets. California: ~60% of consumption remains illicit (2024–25 state data), tied to 58% of jurisdictions banning retail sales and a 15–19% excise tax. Washington: ~50% illicit (estimated, no comprehensive state study exists), at the highest cannabis excise tax in the US (37%). Colorado is a partial confirming contrast — a 2018 state study found in-state demand "fully absorbed" into the regulated market, with residual illicit activity mostly interstate diversion, consistent with Colorado's broader retail access and lower friction — but current (2024–26) Colorado data could not be verified, so this leg rests on older evidence than CA/WA's.
Opioid settlement funds — the number itself is a moving target
Total is genuinely unresolved as a single figure: KFF cites >50–54B, anindependenttracker(OpioidSettlementTracker.com)putstherunningtotalat * *58.58B as of April 2026**. Treat $50–58B over ~15–18 years as a bracket, not a fixed figure — this is expected given new settlements keep closing, not a sourcing failure.
Legal cannabis market design
The CA/WA contrast is the cleanest natural comparison in the whole filing for §10's cannabis architecture: both are mature legal markets, both still have large illicit shares, and both tie that persistence explicitly (in their own state data) to the effective cost of legality — tax rate plus regulatory/access friction — relative to the untaxed alternative. This directly informs §10: cannabis legalization is not a switch, it's a market-design problem with a tunable knob (tax + access), and Washington's 37% rate — the highest in the nation — combined with a declining sales trend (down ~21% from its 2021 peak) is a live cautionary data point for any future legal-drug-market design in this filing's other architectures.
Private equity in treatment — quality/outcomes remains a genuine open gap
PE owns ~7.1% of SUD facilities nationally but **~30% of Opioid Treatment Programs (methadone clinics)** specifically — a striking concentration in exactly the dispensing-restricted, high-margin segment §4 already flagged as legally cornered. The most rigorous study located (Reimer, King & Busch, Health Affairs Nov. 2025) found PE acquisition increases Medicare/Medicaid acceptance (cutting against a simple cream-skimming story) but explicitly could not measure care quality or outcomes — congressional investigations (Markey, Braun, Hassan into Acadia, BayMark, New Season) have outpaced what the peer-reviewed literature has actually established.
Pharma pricing: naloxone is a genuine success story, buprenorphine pricing is a live perverse incentive
Naloxone affordability has improved markedly since OTC approval — mean out-of-pocket cost fell from $90.93 to $62.67, and California's CalRx generic deal reached $24/twin-pack. Buprenorphine tells the opposite story: identical drug formulations marketed for pain cost up to 14x more (self-pay) and 50.5x more (Medicaid) than formulations marketed for OUD — meaning generic oxycodone, a riskier full agonist, can be 7.8–31.3x cheaper than pain-formulation buprenorphine, a structural incentive toward riskier prescribing that compounds §4's dispensing-access barriers rather than substituting for them.
Alcohol industry as the incumbent-lobby template
Alcohol spent $541M on federal lobbying 1998–2020 (peer-reviewed, Milbank Quarterly), a fraction of tobacco's $755M over the same window, concentrated among four firms. Documented and directly relevant to §10/§11: alcohol firms, having historically opposed cannabis legalization, pivoted after ~2018 to lobbying for cannabis tax/regulatory treatment "at least comparable" to alcohol's own regime — using existing lobbying infrastructure to shape a legal competitor's ground rules rather than block it outright, motivated by evidence that legal cannabis measurably depresses alcohol sales in some markets. This is the clearest concrete precedent in the filing for what any newly-legal drug-market architecture should expect once mature: not opposition from the existing legal-drug lobby, but active shaping of the new market's rules.
Implications for §10/§11
- §10's cannabis-market architecture should be designed around the CA/WA tax-and-access lesson explicitly, not just scored on "legalize: yes/no."
- The settlement-fund governance gap (H7.1) is itself a §10-relevant finding: it argues for an architecture component that improves spending oversight/evidence requirements on money already appropriated and flowing, which per §11's sequencing logic could be one of the cheapest, fastest-acting levers available — no new appropriation needed, just better conditions on disbursement.
- The buprenorphine pricing disparity is a distinct lever from §4's regulatory findings — a pricing-transparency or reference-pricing fix could be pursued independently of (and faster than) any dispensing-regulation change.
Confidence: Moderate
Strong on settlement-governance findings (three co-producing institutions), CA/WA cannabis data (state regulatory agencies), and alcohol lobbying figures (peer-reviewed). Weaker on: the exact settlement total (genuinely a moving target, not resolvable to one number), Colorado's current illicit-market share (only 2018 data located), and PE's effect on treatment quality (an open evidence gap in the literature itself, not a research shortfall here).